155 related articles for article (PubMed ID: 36917897)
21. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.
Qaddoumi I; Orisme W; Wen J; Santiago T; Gupta K; Dalton JD; Tang B; Haupfear K; Punchihewa C; Easton J; Mulder H; Boggs K; Shao Y; Rusch M; Becksfort J; Gupta P; Wang S; Lee RP; Brat D; Peter Collins V; Dahiya S; George D; Konomos W; Kurian KM; McFadden K; Serafini LN; Nickols H; Perry A; Shurtleff S; Gajjar A; Boop FA; Klimo PD; Mardis ER; Wilson RK; Baker SJ; Zhang J; Wu G; Downing JR; Tatevossian RG; Ellison DW
Acta Neuropathol; 2016 Jun; 131(6):833-45. PubMed ID: 26810070
[TBL] [Abstract][Full Text] [Related]
22. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
23. Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.
Deng MY; Sill M; Chiang J; Schittenhelm J; Ebinger M; Schuhmann MU; Monoranu CM; Milde T; Wittmann A; Hartmann C; Sommer C; Paulus W; Gärtner J; Brück W; Rüdiger T; Leipold A; Jaunmuktane Z; Brandner S; Giangaspero F; Nozza P; Mora J; Morales la Madrid A; Cruz Martinez O; Hansford JR; Pietsch T; Tietze A; Hernáiz-Driever P; Stoler I; Capper D; Korshunov A; Ellison DW; von Deimling A; Pfister SM; Sahm F; Jones DTW
Acta Neuropathol; 2018 Aug; 136(2):239-253. PubMed ID: 29766299
[TBL] [Abstract][Full Text] [Related]
24. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
Lu VM; Alvi MA; McDonald KL; Daniels DJ
J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
[TBL] [Abstract][Full Text] [Related]
26. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.
Tian Y; Rich BE; Vena N; Craig JM; Macconaill LE; Rajaram V; Goldman S; Taha H; Mahmoud M; Ozek M; Sav A; Longtine JA; Lindeman NI; Garraway LA; Ligon AH; Stiles CD; Santagata S; Chan JA; Kieran MW; Ligon KL
J Mol Diagn; 2011 Nov; 13(6):669-77. PubMed ID: 21884820
[TBL] [Abstract][Full Text] [Related]
27. Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14.
Deng MY; Sill M; Sturm D; Stichel D; Witt H; Ecker J; Wittmann A; Schittenhelm J; Ebinger M; Schuhmann MU; Figarella-Branger D; Aronica E; Staszewski O; Preusser M; Haberler C; Lauten M; Schüller U; Hartmann C; Snuderl M; Dunham C; Jabado N; Wesseling P; Deckert M; Keyvani K; Gottardo N; Giangaspero F; von Hoff K; Ellison DW; Pietsch T; Herold-Mende C; Milde T; Witt O; Kool M; Korshunov A; Wick W; von Deimling A; Pfister SM; Jones DTW; Sahm F
Neuropathol Appl Neurobiol; 2020 Aug; 46(5):422-430. PubMed ID: 31867747
[TBL] [Abstract][Full Text] [Related]
28. [The 2021 WHO classification of tumours of the central nervous system].
Figarella-Branger D; Appay R; Metais A; Tauziède-Espariat A; Colin C; Rousseau A; Varlet P
Ann Pathol; 2022 Oct; 42(5):367-382. PubMed ID: 34865882
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of distinct genetic entities in pediatric diffuse glioma WHO-grade II-Report from the German/Swiss SIOP-LGG 2004 cohort.
Falkenstein F; Gessi M; Kandels D; Ng HK; Schmidt R; Warmuth-Metz M; Bison B; Krauss J; Kortmann RD; Timmermann B; Thomale UW; Albert MH; Pekrun A; Maaß E; Gnekow AK; Pietsch T
Int J Cancer; 2020 Oct; 147(8):2159-2175. PubMed ID: 32239677
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
Sonoda Y
Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
[TBL] [Abstract][Full Text] [Related]
31. Clinical, pathologic, and genomic characteristics of two pediatric glioneuronal tumors with a CLIP2::MET fusion.
Chapman N; Greenwald J; Suddock J; Xu D; Markowitz A; Humphrey M; Cotter JA; Krieger MD; Hawes D; Ji J
Acta Neuropathol Commun; 2024 Apr; 12(1):63. PubMed ID: 38650040
[TBL] [Abstract][Full Text] [Related]
32. Molecular pathology of paediatric central nervous system tumours.
Chiang JC; Ellison DW
J Pathol; 2017 Jan; 241(2):159-172. PubMed ID: 27701736
[TBL] [Abstract][Full Text] [Related]
33. Whole genome analysis from microdissected tissue revealed adult supratentorial grade II-III gliomas are divided into clinically relevant subgroups by genetic profile.
Hirose Y; Sasaki H; Miwa T; Ohba S; Ikeda E; Abe M; Ikeda S; Kobayashi M; Kawase T; Hasegawa M; Yoshida K
Neurosurgery; 2011 Aug; 69(2):376-90. PubMed ID: 21358357
[TBL] [Abstract][Full Text] [Related]
34. Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients.
Parisi R; Patel RR; Rood G; Bowden A; Turco G; Korones DN; Andolina JR; Comito M; Barth M; Weintraub L
Pediatr Blood Cancer; 2023 Mar; 70(3):e30139. PubMed ID: 36573296
[TBL] [Abstract][Full Text] [Related]
35. Supratentorial CNS-PNETs in children; a Swedish population-based study with molecular re-evaluation and long-term follow-up.
Schepke E; Löfgren M; Pietsch T; Kling T; Nordborg C; Olsson Bontell T; Holm S; Öberg A; Nyman P; Eliasson-Hofvander M; Sabel M; Lannering B; Carén H
Clin Epigenetics; 2023 Mar; 15(1):40. PubMed ID: 36895035
[TBL] [Abstract][Full Text] [Related]
36. [Histological and molecular classification of gliomas].
Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
[TBL] [Abstract][Full Text] [Related]
37. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
38. WES data from 286 diffuse gliomas under the 2021 WHO Classification of Tumors of the Central Nervous System.
Zhao Z; Zhang KN; Sun Z; Yang C; Wang Q; Li G; Wang Z; Zeng F; Chai R; Qian Z; Wang Z; Liu Y; Ma W; Wu F; Jiang T
Sci Data; 2022 Nov; 9(1):692. PubMed ID: 36369198
[TBL] [Abstract][Full Text] [Related]
39. WHO 2016 Classification of gliomas.
Wesseling P; Capper D
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):139-150. PubMed ID: 28815663
[TBL] [Abstract][Full Text] [Related]
40. Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss.
Kim YH; Nonoguchi N; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Mariani L; Giangaspero F; Tanaka Y; Nakazato Y; Vital A; Mittelbronn M; Perry A; Ohgaki H
Brain Pathol; 2012 Nov; 22(6):834-40. PubMed ID: 22568401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
